{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T13:52:56Z","timestamp":1793368376513,"version":"4.5.0"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T00:00:00Z","timestamp":1701648000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill &amp; Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-006006"],"award-info":[{"award-number":["INV-006006"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.vaccine.2023.10.062","type":"journal-article","created":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T18:19:51Z","timestamp":1731003591000},"page":"S1-S8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"S2","title":["Status of HPV disease and vaccination programmes in LMICs: Introduction to special issue"],"prefix":"10.1016","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-2918-8456","authenticated-orcid":false,"given":"Hannah","family":"Borda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Bloem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Akaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Guillaume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Willens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marley","family":"Jurgensmeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirthini","family":"Muralidharan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupali","family":"Limaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2023.10.062_b0005","unstructured":"Global strategy to accelerate the elimination of cervical cancer as a public health problem. Geneva: World Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO."},{"key":"10.1016\/j.vaccine.2023.10.062_b0010","unstructured":"Meites E, Gee J, Unger E, Markowitz L. Chapter 11: Human Papillomavirus. CDC; Aug. 2021. www.cdc.gov\/vaccines\/pubs\/pinkbook\/hpv.html [accessed 14 March 2023]."},{"key":"10.1016\/j.vaccine.2023.10.062_b0015","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2020.552028","article-title":"Epidemiology and burden of human papillomavirus and related diseases, molecular pathogenesis, and vaccine evaluation","volume":"8","author":"Kombe Kombe","year":"2021","journal-title":"Front. Public Health"},{"issue":"97","key":"10.1016\/j.vaccine.2023.10.062_b0025","first-page":"645","article-title":"Human papillomavirus vaccines: WHO position paper (2022 update)","volume":"50","author":"WHO","year":"2022","journal-title":"Weekly Epidemiolog Rec"},{"issue":"12","key":"10.1016\/j.vaccine.2023.10.062_b0030","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1086\/657321","article-title":"Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings","volume":"202","author":"Bruni","year":"2010","journal-title":"J Infect Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2023.10.062_b0035","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1086\/516784","article-title":"A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion","volume":"195","author":"Plummer","year":"2007","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2023.10.062_b0040","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1080\/21645515.2015.1088616","article-title":"Persistent infection with human papillomavirus 16 or 18 is strongly linked with high-grade cervical disease","volume":"12","author":"Radley Saah","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2023.10.062_b0045","unstructured":"WHO International Agency for Research on Cancer. Cervix Uteri Fact Sheet. Published 2021. https:\/\/gco.iarc.fr\/today\/data\/factsheets\/cancers\/23-Cervix-uteri-fact-sheet.pdfr."},{"issue":"2","key":"10.1016\/j.vaccine.2023.10.062_b0050","doi-asserted-by":"crossref","first-page":"e197","DOI":"10.1016\/S2214-109X(22)00501-0","article-title":"Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative","volume":"11","author":"Singh Vignat","year":"2023","journal-title":"Lancet Glob Health"},{"issue":"6","key":"10.1016\/j.vaccine.2023.10.062_b0055","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1097\/QAD.0000000000001765","article-title":"HIV-positive women have higher risk of human papilloma virus infection, precancerous lesions, and cervical cancer","volume":"32","author":"Liu","year":"2018","journal-title":"AIDS"},{"issue":"2","key":"10.1016\/j.vaccine.2023.10.062_b0060","doi-asserted-by":"crossref","first-page":"e161","DOI":"10.1016\/S2214-109X(20)30459-9","article-title":"Estimates of the global burden of cervical cancer associated with HIV","volume":"9","author":"Stelzle Tanaka","year":"2021","journal-title":"Lancet Glob Health"},{"issue":"9","key":"10.1016\/j.vaccine.2023.10.062_b0065","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1093\/cid\/ciy1123","article-title":"Residual or recurrent precancerous lesions after treatment of cervical lesions in human immunodeficiency virus-infected women: a systematic review and meta-analysis of treatment failure","volume":"69","author":"Debeaudrap","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"31","key":"10.1016\/j.vaccine.2023.10.062_b0070","doi-asserted-by":"crossref","first-page":"3749","DOI":"10.1200\/JCO.2016.67.9613","article-title":"HIV infection and survival among women with cervical cancer","volume":"34","author":"Dryden-Peterson","year":"2016","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.vaccine.2023.10.062_b0075","doi-asserted-by":"crossref","first-page":"e180","DOI":"10.1016\/S2214-109X(19)30488-7","article-title":"Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis","volume":"8","author":"de Martel","year":"2020","journal-title":"Lancet Global Health"},{"key":"10.1016\/j.vaccine.2023.10.062_b0080","unstructured":"Viens LJ, Watson M, Markowitz LE, et al. Centers for Disease Control and Prevention (CDC) HSJ. Human Papillomavirus\u2013Associated Cancers\u2014United States, 2008\u20132012. Division of Cancer Prevention and Control, CDC; 2016. https:\/\/www.cdc.gov\/cancer\/hpv\/statistics\/age.htm."},{"key":"10.1016\/j.vaccine.2023.10.062_b0085","series-title":"WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention","author":"Who","year":"2021"},{"issue":"8","key":"10.1016\/j.vaccine.2023.10.062_b0090","doi-asserted-by":"crossref","first-page":"e1115","DOI":"10.1016\/S2214-109X(22)00241-8","article-title":"Cervical cancer screening programmes and age-specific coverage estimates for 202 countries and territories worldwide: a review and synthetic analysis","volume":"10","author":"Bruni","year":"2022","journal-title":"Lancet Global Health"},{"key":"10.1016\/j.vaccine.2023.10.062_b0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.ypmed.2020.106294","article-title":"Accelerating action on cervical screening in lower- and middle-income countries (LMICs) post COVID-19 era","volume":"144","author":"Woo","year":"2021","journal-title":"Prev Med"},{"key":"10.1016\/j.vaccine.2023.10.062_b0100","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.gore.2017.08.004","article-title":"Cervical cancer in low and middle income countries: addressing barriers to radiotherapy delivery","volume":"22","author":"LaVigne Triedman","year":"2017","journal-title":"Gynecol Oncol Rep"},{"key":"10.1016\/j.vaccine.2023.10.062_b0105","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/j.vaccine.2005.09.002","article-title":"Immune responses to human papillomavirus","volume":"24","author":"Stanley","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.10.062_b0110","unstructured":"Prequalified vaccines. WHO; 2023. extranet.who.int\/pqweb\/vaccines\/prequalified-vaccines [accessed 14 March 2023]."},{"key":"10.1016\/j.vaccine.2023.10.062_b0115","unstructured":"Products List. Walvax. en.walvax.com\/products\/products-list?type=62 [accessed 14 March 2023]."},{"issue":"10","key":"10.1016\/j.vaccine.2023.10.062_b0120","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/S1470-2045(22)00567-8","article-title":"HPV vaccination in south Asia: new progress, old challenges","volume":"23","author":"Oncology","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.vaccine.2023.10.062_b0125","unstructured":"Human Papillomavirus Vaccine: Supply and Demand Update UNICEF Supply Division; 2020."},{"issue":"11","key":"10.1016\/j.vaccine.2023.10.062_b0130","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/1348-0421.13024","article-title":"Single-stranded RNA adjuvant enhances the efficacy of 10-valent human papilloma virus-like particle vaccine","volume":"66","author":"Kwak","year":"2022","journal-title":"Microbiol Immunol"},{"key":"10.1016\/j.vaccine.2023.10.062_b0135","unstructured":"A Phase II Study of SCT1000 in Healthy Women Aged 18 to 45 Years. ClinicalTrials.gov, U.S. National Library of Medicine; 28 Oct. 2021, clinicaltrials.gov\/ct2\/show\/NCT05060484 [accessed 14 March 2023]."},{"key":"10.1016\/j.vaccine.2023.10.062_b0140","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2023.1067299","article-title":"Gender neutral HPV vaccination programs: reconsidering policies to expand cancer prevention globally","volume":"11","author":"Dykens","year":"2023","journal-title":"Front Public Health"},{"issue":"12 December","key":"10.1016\/j.vaccine.2023.10.062_b0145","article-title":"Cost-effectiveness of HPV vaccination in 195 countries: a meta-regression analysis","volume":"16","author":"Rosettie","year":"2021","journal-title":"PLoS One"},{"issue":"10224","key":"10.1016\/j.vaccine.2023.10.062_b0150","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S0140-6736(20)30068-4","article-title":"Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries","volume":"395","author":"Brisson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2023.10.062_b0155","unstructured":"International Vaccine Access Center (IVAC). Johns Hopkins Bloomberg School of Public Health. VIEW-hub. www.view-hub.org [accessed: 5\/31\/2023]."},{"key":"10.1016\/j.vaccine.2023.10.062_b0160","unstructured":"Immunization, Vaccines, and Biologicals, HPV Dashboard. WHO. https:\/\/www.who.int\/teams\/immunization-vaccines-and-biologicals\/diseases\/human-papillomavirus-vaccines-(HPV)\/hpv-clearing-house\/hpv-dashboard [accessed 4 September 2023]."},{"key":"10.1016\/j.vaccine.2023.10.062_b0165","unstructured":"Progress and challenges with Achieving Universal Immunization Coverage. WHO, 14 Jul. 2022, www.who.int\/publications\/m\/item\/progress-and-challenges [accessed 31 May 2023]."},{"key":"10.1016\/j.vaccine.2023.10.062_b0170","doi-asserted-by":"crossref","DOI":"10.1093\/heapol\/czad014","article-title":"Feasibility and sustainability of a school-based platform for integrated delivery of HPV vaccination with adolescent health services in Tanzania: qualitative insights from stakeholders","author":"Rosen","year":"2023","journal-title":"Health Policy Plan"},{"key":"10.1016\/j.vaccine.2023.10.062_b0175","unstructured":"Turiho AK, Okello ES, Muhwezi WW, et al. Effect of school-based human papillomavirus (HPV) vaccination on adolescent girls\u2019 knowledge and acceptability of the HPV vaccine in Ibanda District in Uganda HHS public access, vol 18; 2014."},{"issue":"6","key":"10.1016\/j.vaccine.2023.10.062_b0180","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0252310","article-title":"Success of community approach to HPV vaccination in school-based and non-school-based settings in Haiti","volume":"16","author":"Riviere","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2023.10.062_b0185","first-page":"10","article-title":"Human papillomavirus vaccination in South Africa: programmatic challenges and opportunities for integration with other adolescent health services?","author":"Amponsah-Dacosta","year":"2022","journal-title":"Front Public Health"},{"issue":"1","key":"10.1016\/j.vaccine.2023.10.062_b0190","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgph.0001394","article-title":"Acceptability of an integrated school-based HPV vaccination program within two districts of Tanzania: a qualitative descriptive study. Moodley J, editor.","volume":"3","author":"Guillaume","year":"2023","journal-title":"PLOS Glob Public Health"},{"issue":"1","key":"10.1016\/j.vaccine.2023.10.062_b0195","doi-asserted-by":"crossref","first-page":"33","DOI":"10.4314\/ahs.v15i1.5","article-title":"Feasibility of delivering HPV vaccine to girls aged 10 to 15 years in Uganda","volume":"15","author":"Mugisha","year":"2015","journal-title":"Afr Health Sci"},{"key":"10.1016\/j.vaccine.2023.10.062_b0200","unstructured":"WHO HPV Vaccine Global Market Study, April 2022. WHO; 1 Apr. 2022. www.who.int\/publications\/m\/item\/who-hpv-vaccine-global-market-study-april-2022 [accessed 31 May 2023]."},{"key":"10.1016\/j.vaccine.2023.10.062_b0205","unstructured":"Gavi Board Decisions Outline \u2018Year of Renewal\u2019 for Vaccine Alliance. Gavi The Vaccine Alliance; 8 Dec. 2022. www.gavi.org\/news\/media-room\/gavi-board-decisions-outline-year-renewal-vaccine-alliance [accessed 31 May 2023]."},{"issue":"7","key":"10.1016\/j.vaccine.2023.10.062_b0210","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2022.2150454","article-title":"Key decision-making factors for human papillomavirus (HPV) vaccine program introduction in low-and-middle-income-countries: global and national stakeholder perspectives","volume":"18","author":"Guillaume","year":"2022","journal-title":"Hum Vaccin Immunother"},{"issue":"6","key":"10.1016\/j.vaccine.2023.10.062_b0215","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1093\/heapol\/czaa017","article-title":"Health systems constraints and facilitators of human papillomavirus immunization programmes in sub-Saharan Africa: a systematic review","volume":"35","author":"Amponsah-Dacosta","year":"2020","journal-title":"Health Policy Plan"},{"key":"10.1016\/j.vaccine.2023.10.062_b0220","article-title":"National introduction of HPV vaccination in low- and middle-income countries: lessons learned from formal post-introduction evaluations","author":"Murphy","year":"2021","journal-title":"PATH"},{"issue":"6","key":"10.1016\/j.vaccine.2023.10.062_b0225","first-page":"525","article-title":"Lessons learnt during the national introduction of human papillomavirus (HPV) vaccination programmes in 6 African countries: Stakeholders\u2019 perspectives","volume":"110","author":"Abdullahi","year":"2020","journal-title":"S Afr Med J"},{"key":"10.1016\/j.vaccine.2023.10.062_b0230","doi-asserted-by":"crossref","first-page":"A10","DOI":"10.1016\/j.vaccine.2021.08.042","article-title":"National introduction of HPV vaccination in Senegal\u2014successes, challenges, and lessons learned","volume":"40","author":"Casey","year":"2022","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2023.10.062_b0235","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2471\/BLT.11.097253","article-title":"Atteinte d\u2019un niveau de couverture \u00e9lev\u00e9 pour le programme national Rwandais de vaccination contre le papillomavirus humain","volume":"90","author":"Binagwaho","year":"2012","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.vaccine.2023.10.062_b0240","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/ijgo.12186","article-title":"Progress in HPV vaccination in low- and lower-middle-income countries","volume":"138","author":"LaMontagne","year":"2017","journal-title":"Int J Gynecol Obstetr"},{"issue":"1","key":"10.1016\/j.vaccine.2023.10.062_b0245","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/ijgo.13482","article-title":"Acting on the call: A framework for action for rapid acceleration of access to the HPV vaccination in low- and lower-middle-income countries","volume":"152","author":"Kumar","year":"2021","journal-title":"Int J Gynecol Obstetr"},{"issue":"5","key":"10.1016\/j.vaccine.2023.10.062_b0250","doi-asserted-by":"crossref","first-page":"496","DOI":"10.3390\/vaccines9050496","article-title":"Stakeholders\u2019 understandings of human papillomavirus (HPV) vaccination in sub-Saharan Africa: a rapid qualitative systematic review","volume":"9","author":"Deignan","year":"2021","journal-title":"Vaccines"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2023.10.062_b0255","doi-asserted-by":"crossref","first-page":"A17","DOI":"10.1016\/j.vaccine.2021.07.024","article-title":"Human papillomavirus (HPV) vaccine introduction in Sikkim state: best practices from the first statewide multiple-age cohort HPV vaccine introduction in India-2018-2019","volume":"40","author":"Ahmed","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.10.062_b0260","doi-asserted-by":"crossref","DOI":"10.1186\/s13012-018-0846-2","article-title":"Human papillomavirus vaccine delivery in Mozambique: identification of implementation performance drivers using the Consolidated Framework for Implementation Research (CFIR)","volume":"13","author":"Soi","year":"2018","journal-title":"Implementation Sci"},{"key":"10.1016\/j.vaccine.2023.10.062_b0265","unstructured":"Immunization Agenda 2030: A Global Strategy To Leave No One Behind. WHO; 1 Apr. 2020, www.who.int\/publications\/m\/item\/immunization-agenda-2030-a-global-strategy-to-leave-no-one-behind [accessed 31 May 2023]."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23012756?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23012756?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T20:21:10Z","timestamp":1786220470000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23012756"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":52,"alternative-id":["S0264410X23012756"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.10.062","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Status of HPV disease and vaccination programmes in LMICs: Introduction to special issue","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.10.062","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}